Introduction
Thyroid hormone is essential for the maturation of many tissues, including the brain, as well as for the development of thermogenesis in the neonatal period. The thyroid function of the preterm infant is affected by the relative immaturity of the hypothalamo-pituitary-thyroid axis, along with other factors such as the incidence of diseases or the use of some drugs. An increase in the levels of free thyroxine (FT 4 ) and thyrotropin (TSH) occurs after birth, similar to that observed in full-term newborns, but at a lesser magnitude in lower gestational age or greater comorbidity. Transient hypothyroxinemia of prematurity, defined as a temporary reduction in FT 4 values without increase of TSH values, can last between six and eight weeks and could explain some degree of delay in the long-term neurodevelopment observed in very low birth weight premature infants 1 , however, this condition by itself does not produce a lower IQ or long-term motor alterations, according to the results of a cohort studied until 19 years of age 2 . Hypothyroxinemia usually occurs in ill preterm infants and it is a diagnostic challenge in order to differentiate it from thyroid dysfunction in the critically ill patient. Currently, there is no consensus about normal FT 4 values in preterm infants [3] [4] [5] , since the abnormality criterion based on the FT 4 value, two standard deviations below the average, seems not to reflect the absence of morbidity in all cases. Previous studies report a prevalence of this disorder in very preterm and extremely preterm infants of 12.2% to 23.5% depending on the cutoff point used [6] [7] [8] [9] .
The benefits of the administration of thyroid hormone in preterm infants are not yet completely clear. In a Cochrane systematic review that analyzed the results of five randomized clinical trials, the authors conclude that there is no significant difference in mortality (RR 0.70 -95% CI 0.42 to 1.17), risk of cerebral palsy (RR 0.72 -95% CI 0.28 to 1.84), or abnormal neurological development at six years of age (RR 0.66 -95% CI 0.22 to 1.99) 10 . However, Van Wassenaer (2002) reports significant differences in parameters that assess neurodevelopment at two and five years of age when comparing the results of preterm infants treated with thyroid hormone with plasma FFT4evels below the 25th percentile (0.78 to 0.97 ng/dl) compared with 75% of higher values (0.97 to 1.63 ng/dl) 11 . There is also evidence that high levels of thyroid hormones are also associated with adverse events 12 . The objective was to determine the distribution of FT 4 and TSH hormone values in newborns younger than 32 weeks or 1,500 g of birth weight at 15 days of chronological age, in the neonatology service of the Dr. Hernán Henríquez Aravena Hospital, Temuco.
Patients and Method Design
A cross-cutting study was conducted. Clinical variables and results of FT 4 and TSH serum value were collected from an anonymized statistical database of discharge summary from the neonatology service of Dr. Hernán Henríquez Aravena Hospital, Temuco, Chile. Iodine antiseptic solutions are not used in the obstetric and neonatal services of our center, which may alter thyroid hormone concentrations.
Laboratory methods
The laboratory method used for the determination of both levels was chemiluminescent microparticles immunoassay on an Architect analyzer. The samples correspond to venous blood taken at 15 days of chronological age.
Patients
All preterm infants under 32 weeks or less than 1,500 g of birth weight, hospitalized in the Neonatology Service of the Dr. Hernán Henríquez Aravena Hospital in Temuco, between January 1, 2014, and December 31, 2015, were included.
Statistical analysis
The measures of central tendency, dispersion and position were estimated; Pearson's chi-square test was used for associations between categorical variables, and T-Test or ANOVA was used for comparisons between continuous variables. A minimum sample size of 208 subjects was calculated, considering an alpha=0.05, with a level of significance at 95% and an expected proportion in the population of 20%. For the statistical analysis, STATA 13 software was used.
Ethical Considerations
The protocol was approved by the scientific ethics committee of the Universidad Mayor.
Results
The sample consisted of 308 newborns, which were categorized into three groups according to gestational age: 23 to 27 weeks, 28 to 30 weeks and 31 to 34 weeks. 10% (n=31) of the included newborns were connected to mechanical ventilation at 15 days of chronological age, none of the included patients received vasoactive or corticosteroid drugs during the sampling period. Table 1 shows the results of the main clinical variables analyzed. Newborns with a weight lower than p10 were considered small for gestational age according to the Alarcon-Pittaluga growth curves. Figure 1 shows the relative distribution of FT 4 and TSH values of the 308 newborns included, both variables have asymmetric distributions. There are significant differences in average values and the distribution of FT 4 values among the groups categorized by gestational age. Figure 2 shows that these differences were not significant in the distribution of TSH values by gestational age. Table 2 shows the position and dispersion measurements of the FT 4 and TSH levels for each category and overall results. In our sample, the 25th percentile of FT4 was 0.75 ng/dl for the 23 to 27 week group, 0.9 ng/dl for the 28 to 30 week group, and 1 ng/dl for the 31 to 34 week group. The 10th percentile of FT4 was 0.61 ng/dl for the 23 to 27 week group, 0.81 ng/dl for the 28 to 30 week group, and 0.91 ng/dl for the 31 to 34 week group. 
Discussion
The determination of FT4 in very preterm and extremely preterm infants is a standard care in national and global neonatal units, however, there is controversy about what levels are considered normal in this group of newborns. Adams (1995) in a cross-sectional study of 104 preterm infants, with measurements at seven days of age, reports an average FT4 value of 2.4 ng/ dl for the 31 to 33 weeks of gestational age range, 2 ng/ dl for the 28 to 30 weeks range, and 1.4 for the 25 to 27 weeks range 13 . Williams (2004) in a prospective study of 475 preterm infants, in a measurement of thyroid hormones in cord blood at seven, 15 and 28 days, reports average FT4 values at 15 days of life of 2 ng/dl for the 31 to 34 weeks of gestational age range, 1.6 ng/ dl for the 28 to 30 weeks range, and 1.4 for the 23 to 27 weeks range 14 . Our results differ from the abovementioned studies when analyzing the results of FT4 and TSH in 308 preterm infants at 15 days of chronological age, the average values we report are lower for each gestational age range. The reasons for these differences can mainly be explained by the different laboratory tests used in each center and the inclusion criteria for the studied subjects, our study includes a sample of preterm infants under 30 weeks, larger than that of previous publications 13 , our data also show a much smaller dispersion than previously published data. In addition to this, we report position measures such as the 10th percentile or the 25th percentile for three gestational age categories at 15 days of chronological age, which present statistically significant differences (p = 0.000), these values could be used as a cut-off point to determine pathological conditions such as transient hypothyroxinemia of prematurity. The average TSH values do not show significant differences between the three categories of gestational age studied; these results coincide with previous prospective studies 15 .
The criteria used to define hypothyroxinemia and, therefore, its prevalence has important variations in previous studies, most of these consider a single cutoff point independent of gestational age. Lee (2015) reports a prevalence of thyroid dysfunction of 12.2% in a sample of 246 newborns under 1.500 g, considering FT4 < 0.7 ng/dl and TSH < 20 mIU/l 6 as cut-off point; Uchiyama (2015) reports a prevalence of 20% in a sample of 500 newborns under 30 weeks, considering FT4 < 0.8 ng/dl and TSH < 10 mIU/l 7 as cut-off point; and Lim (2014) reports a prevalence of 23.5% in a sample of 196 newborns under 1,500 g, considering FT4 levels below 0.8 ng/dl and TSH < 5.05 mIU/l (8) as cut-off point 8 . We observed significant differences in the average FT4 values, 25th percentile and 10th percentile when categorizing by gestational age, and other publications also suggest the use of cut-off points according to gestational age ranges. Demirel (2013) reports a prevalence of 15.3% in a sample of 124 newborns under 35 weeks, using FT4 cut-off points categorized by gestational age: < 0.6 ng/dl for infants of 25 to 27 weeks, < 0.8 ng/dl for infants of 28 to 30 weeks and < 1 ng/dl for infants of 31 to 34 weeks 9 , which are consistent with the 10th percentile of our data, except in the 31 to 34 weeks group in which we observed a lower value (p10 = 0.91 ng/dl).
We identified some limitations of this study, first of all, the study includes patients from a single center, which may limit the ability to generalize the results; second, the study is based on retrospective data stored in statistical databases, therefore, there are variables that could not be analyzed such as triiodothyronine levels, maternal thyroid diseases, to apply severity scales in the included subjects, among others.
In conclusion, we established the distribution of FT4 and TSH levels in our population of very preterm and extremely preterm infants, finding differences with previous studies. We also found significant differences in the average value, 10th and 25the percentile in three gestational age ranges, these results could be used as a cut-off point to determine pathological conditions such as transient hypothyroxinemia of prematurity and use them as a reference for therapeutic targets. We also consider necessary to complement our results with long-term prospective studies in the studied population.
